Denaverine

Denaverine
Clinical data
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
  • Gr 1 (Germany)
Routes of
administration		intramuscular injection, suppositories
ATCvet code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability8% (suppositories),
37% (oral solution)
Metabolismmainly hepatic, at least 11 metabolites
Elimination half-life34 hours
Identifiers
IUPAC name
  • 2-(Dimethylamino)ethyl (2-ethylbutoxy)diphenylacetate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H33NO3
Molar mass383.532 g·mol−1
3D model (JSmol)
SMILES
  • CCC(CC)COC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCCN(C)C
InChI
  • InChI=1S/C24H33NO3/c1-5-20(6-2)19-28-24(21-13-9-7-10-14-21,22-15-11-8-12-16-22)23(26)27-18-17-25(3)4/h7-16,20H,5-6,17-19H2,1-4H3 ☒N
  • Key:FPTOUQZVCUIPHY-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Denaverine is an antispasmodic drug. It was developed in Germany and patented in 1974. Denaverine hydrochloride is used in veterinary medicine under the trade name Sensiblex as a muscle relaxant for the myometrium of cows and dogs during parturition.[1] Under the trade name Spasmalgan, it has also been used in humans for the treatment of urogenital and gastrointestinal spasms.[2]

Mechanism of action

Denaverine, like papaverine, acts as a phosphodiesterase inhibitor. Additionally, it has anticholinergic effects.[3]

References

  1. ↑ Committee for Veterinary Medicinal Products: Denavering Hydrochloride Summary Report
  2. ↑ Dootz H, Kuhlmann A, Hoffmann K (eds.). Rote Liste (in German) (2005 ed.). Aulendorf: Editio Cantor. 77 023. ISBN 3-87193-306-6.
  3. ↑ Dinnendahl V, Fricke U, eds. (2010). Arzneistoff-Profile (in German). Vol. 4 (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.